Healthcare - Biotechnology - NASDAQ - US
$ 0.6704
5.46 %
$ 13.1 M
Market Cap
-0.25
P/E
CASH FLOW STATEMENT
-10.8 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
8.76 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Ensysce Biosciences, Inc.
| Net Income | -10.6 M |
| Depreciation & Amortization | 326 K |
| Capital Expenditures | 2 |
| Stock-Based Compensation | 879 K |
| Change in Working Capital | -947 K |
| Others | -304 K |
| Free Cash Flow | -10.8 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (10.6) | (24.2) | (29.1) | (0.2) | 0.4 | (1.3) | 31.2 K |
| Depreciation & Amortization | 0.3 | 0 | 151 | 201 | 201 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 14.6 | (2.4) | 1.76 K | 1.76 K | 0 |
| Stock Based Compensation | 0.9 | 1.1 | 0.1 | 0.2 | 6.0 | 0 | 0 |
| Other Operating Activities | (0.4) | (0.2) | 7.5 | 1.0 | 8.2 | (0.3) | (0.2) |
| Change in Working Capital | (0.9) | 5.5 | (1.3) | 0.2 | 2.5 | 0.3 | (0.1) |
| Cash From Operations | (10.8) | (17.9) | (8.2) | (1.2) | 11.0 | (1.2) | (0.3) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Items | 2 | 4.5 K | 0 | 183.4 | (0.6) | 0.8 | (200.0) |
| Cash From Investing Activities | 0 | 4.5 K | 0 | 183.4 | (0.6) | 0.8 | (200.0) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (11.6) | 0 | 0 |
| Total Debt Repaid | 0.6 | 6.1 | 13.9 | 1.1 | 0.4 | 0 | 0 |
| Dividends Paid | 0 | (0.9) | (803 140.0) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (0.9) | 3.6 | (0.2) | 20 | 0.2 | 0 | 0 |
| Cash From Financing Activities | 8.8 | 8.8 | 20.3 | 1.1 | (11.0) | 32 K | 202.3 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (2.0) | (9.1) | 12.1 | (0.1) | (0.6) | (0.4) | 2.1 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (10.8) | (17.9) | (8.2) | (1.2) | 11.0 | (1.2) | (0.3) |